Robert E. Waltermire - 24 Feb 2022 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Reporting relationship: Senior VP, Chief Pharma Dev.
Issuer ticker: MDGL
Reported as of: 24 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Feb 2022, 19:17:26 UTC
Prior SEC filing: 04 Aug 2021
Next SEC filing: 18 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Brian J. Lynch, As attorney-in-fact for Reporting Person

Key filing fact

Robert E. Waltermire filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 24 Feb 2022.

Key facts

This page summarizes Robert E. Waltermire's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Feb 2022, 19:17.

Change

Previous filing in this sequence was filed on 04 Aug 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDGL transaction Derivative

Call Option

Award

Transaction value: $0
Shares: +12,250
Change %
Price: $0.000000
Shares after: 12,250
Date: 24 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,250
Exercise price: $87.09
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests as to 25% of the shares on the first anniversary of the date of grant (02/24/2023) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.